Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

GlaxoSmithKline210 enrolled

Overview

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

210

Conditions

Impetigo

Interventions

SB-275833 ointment, 1%DRUG

Eligibility

Sex: ALLMin age: 9 Months

Medical Language ↔ Plain English

Inclusion criteria: * Must have primary impetigo with total lesion area being 100 square centimeters or less. * Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures. Exclusion Criteria: * Any signs and symptoms of systemic infection. * Any serious underlying disease that could be imminently life threatening.

Locations (22)

GSK Investigational Site

Bangalore, India

GSK Investigational Site

Hyderabad, India

Outcomes

Primary Outcomes

Clinical response of impetigo at end of therapy visit. Clinical response of success is defined as no further need for antibacterial treatment.

Secondary Outcomes

Clinical response of impetigo at follow up visit. Impetigo lesion area at end of therapy and follow up visits.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.